Literature DB >> 11207022

The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures.

G W Waterer1, R G Wunderink.   

Abstract

The value of blood cultures in community-acquired pneumonia (CAP) has been questioned. At issue is the potential for blood cultures to change management. We prospectively studied the yield and impact of blood cultures in patients admitted with CAP. Two hundred and nine subjects had at least two blood cultures prior to receiving antibiotics. The severity of CAP was graded using the Pneumonia Severity Index (PSI). Twenty-nine patients (13.9%) had a pathogen identified by blood culture. The yield of blood cultures increased with PSI grade (I--5.3%, II--10.2%, III--10.3%, IV--16.1%, V--26.7%), as did the likelihood of blood cultures changing antibiotic therapy (I to III--0%, IV--9.7%, V--20.0%). One hundred and seventy-nine (85.6%) patients received a quinolone, limiting the impact of pathogens resistant to beta-lactams. Four of 16 patients (25.0%) with a culture (blood or sputum)-guided change in antibiotic therapy died, compared to five of 31 patients (16.1%) who had an empiric change. Blood cultures are of minimal value in mild to moderate CAP, and should be limited to patients with PSI grade IV or V CAP unless a specific risk factor for pathogens resistant to the empiric therapy is present.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207022     DOI: 10.1053/rmed.2000.0977

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  33 in total

1.  Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department.

Authors:  S G Campbell; T J Marrie; R Anstey; S Ackroyd-Stolarz; G Dickinson
Journal:  Emerg Med J       Date:  2003-11       Impact factor: 2.740

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 3.  Updated review of blood culture contamination.

Authors:  Keri K Hall; Jason A Lyman
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 4.  Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections.

Authors:  K Loens; L Van Heirstraeten; S Malhotra-Kumar; H Goossens; M Ieven
Journal:  J Clin Microbiol       Date:  2008-11-19       Impact factor: 5.948

5.  Blood culture use in the emergency department in patients hospitalized with respiratory symptoms due to a nonpneumonia illness.

Authors:  Anil N Makam; Andrew D Auerbach; Michael A Steinman
Journal:  J Hosp Med       Date:  2014-04-22       Impact factor: 2.960

6.  Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia.

Authors:  M M van der Eerden; F Vlaspolder; C S de Graaff; T Groot; H M Jansen; W G Boersma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-04       Impact factor: 3.267

Review 7.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  30-day mortality in UK patients with bacteraemic community-acquired pneumonia.

Authors:  M Melzer; C Welch
Journal:  Infection       Date:  2013-05-24       Impact factor: 3.553

9.  Limited usefulness of initial blood cultures in community acquired pneumonia.

Authors:  J Corbo; B Friedman; P Bijur; E J Gallagher
Journal:  Emerg Med J       Date:  2004-07       Impact factor: 2.740

10.  Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures?

Authors:  Samuel George Campbell; R Andrew McIvor; Vincent Joanis; David Graydon Urquhart
Journal:  World J Emerg Med       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.